ClinicalTrials.gg
CompletedNCT02172261Updated Jun 24, 2014

Relative Bioavailability of BI 10773 and Glimepiride in Healthy Male Volunteers

A Phase 1 interventional study of BI 10773 and Glimepiride in Healthy, sponsored by Boehringer Ingelheim. Completed. Open to male participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-06-24.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Male
01

Study summary

The objective was to investigate whether there was a drug-drug interaction between BI 10773 and glimepiride when co-administered. Therefore, the relative bioavailabilities of BI 10773 and glimepiride were determined when both drugs were given in combination compared to multiple oral doses of BI 10773 once daily alone and a single oral dose of glimepiride given alone.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male volunteers according to the following criteria: Based upon a complete medical history, including the physical examination, vital signs (BP, PR), 12-lead , clinical laboratory tests
  • Age 18 to 50 years (incl.)
  • (Body Mass Index) 18.5 to 29.9 kg/m2 (incl.)
  • Signed and dated written prior to admission to the study in accordance with GCP (Good Clinical Practice) and the local legislation

Exclusion criteria

Exclusion Criteria:

  • Any finding of the medical examination (including BP (Blood Pressure, PR (Pulse Rate) and (Electrocardiogram)) deviating from normal and of clinical relevance
  • Any evidence of a concomitant disease
  • Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  • Surgery of the gastrointestinal tract (except appendectomy)
  • Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
  • History of relevant orthostatic hypotension, fainting spells or blackouts
  • Chronic or relevant acute infections
  • History of relevant allergy/ (including allergy to drug or its )
  • Intake of drugs with a long half-life (> 24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial
  • Participation in another trial with an drug within two months prior to administration or during the trial
  • Smoker (> 10 cigarettes or > 3 cigars or > 3 pipes/day)
  • Inability to refrain from smoking on trial days
  • Alcohol abuse (more than 30 g/day)
  • Drug abuse
  • Blood donation (more than 100 mL within four weeks prior to administration or during the trial)
  • Excessive physical activities (within one week prior to administration or during the trial)
  • Any laboratory value outside the reference range that is of clinical relevance
  • Inability to comply with dietary regimen of trial site
  • Glucose-6-phosphate dehydrogenase deficiency
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Sequence ABC

    1. Treatment A: BI 10773 once daily from day 1 to 5 2. Treatment B: BI 10773 and glimepiride once on day 1 3. Treatment C: Glimepiride once on day 1

    Drug: BI 10773 · Drug: Glimepiride

  • Experimental
    Sequence CAB

    1. Treatment C: Glimepiride once on day 1 2. Treatment A: BI 10773 once daily from day 1 to 5 3. Treatment B: BI 10773 and glimepiride once on day 1

    Drug: BI 10773 · Drug: Glimepiride

Interventions

06

What researchers measure

Primary outcomes

  1. AUCτ,ss (area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ) of BI 10773

    Time frame: up to 5 days

  2. Cmax,ss (maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ) of BI 10773

    Time frame: up to 5 days

  3. AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity) of glimepiride

    Time frame: up to 4 days

  4. Cmax (maximum measured concentration of the analyte in plasma) of glimepiride

    Time frame: up to 4 days

Secondary outcomes

  1. AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point) of glimepiride

    Time frame: up to 4 days

  2. tmax (time from dosing to the maximum concentration of the analyte in plasma) of glimepiride

    Time frame: up to 4 days

  3. λz (terminal rate constant in plasma) of glimepiride

    Time frame: up to 4 days

  4. t½ (terminal half-life of the analyte in plasma) of glimepiride

    Time frame: up to 4 days

  5. MRTpo (mean residence time of the analyte in the body after po administration) of glimepiride

    Time frame: up to 4 days

  6. CL/F (apparent clearance of the analyte in the plasma after extravascular administration) of glimepiride

    Time frame: up to 4 days

  7. Vz/F (apparent volume of distribution during the terminal phase λz following an extravascular dose) of glimepiride

    Time frame: up to 4 days

  8. tmax,ss (time from last dosing to maximum concentration of the analyte in plasma at steady state over a uniform dosing interval τ) of BI 10773

    Time frame: up to 5 days

  9. Aet1-t2 (amount of analyte eliminated in urine over the time interval from t1 to t2) of glimepiride

    Time frame: 1 hour pre-dose and 0-2, 2-4, 4-8, 8-12, 12-24 after administration on day 1

  10. fet1-t2 (fraction of analyte excreted unchanged in urine over the time interval from t1 to t2) of glimepiride

    Time frame: 1 hour pre-dose and 0-2, 2-4, 4-8, 8-12, 12-24 after administration on day 1

  11. CLR (renal clearance of the analyte) of glimepiride

    Time frame: 1 hour pre-dose and 0-2, 2-4, 4-8, 8-12, 12-24 after administration on day 1

  12. λz,ss (terminal rate constant of analyte in plasma at steady-state) of BI 10773

    Time frame: up to 5 days

  13. t½,ss (terminal half-life of analyte in plasma at steady-state) of BI 10773

    Time frame: up to 5 days

  14. MRTpo,ss (mean residence time of the analyte in the body at steady state after oral administration) of BI 10773

    Time frame: up to 5 days

  15. CL/F,ss (apparent clearance of the analyte in the plasma after extravascular administration at steady state) of BI 10773

    Time frame: up to 5 days

  16. Vz/F,ss (apparent volume of distribution during the terminal phase λz at steady state following extravascular administration) of BI 10773

    Time frame: up to 5 days

  17. Aet1-t2,ss (amount of analyte eliminated in urine at steady state over a uniform dosing interval τ) of BI 10773

    Time frame: 1 hour pre-dose and 0-2, 2-4, 4-8, 8-12, 12-24 after administration on day 1 and 5

  18. fet1-t2,ss (fraction of analyte excreted unchanged in urine at steady state over a uniform dosing interval τ) of BI 10773

    Time frame: 1 hour pre-dose and 0-2, 2-4, 4-8, 8-12, 12-24 after administration on day 1 and 5

  19. CLR,ss (renal clearance of the analyte at steady state) of BI 10773

    Time frame: 1 hour pre-dose and 0-2, 2-4, 4-8, 8-12, 12-24 after administration on day 1 and 5

  20. UGE0-24 (Urinary glucose excretion of the analyte in urine over the time interval from time zero to 24 h)

    Time frame: 1 hour pre-dose and 0-2, 2-4, 4-8, 8-12, 12-24 after administration on days 1 and 5

  21. Number of patients with abnormal findings in physical examination

    Time frame: Baseline and within 3-14 days after last glimepiride administration

  22. Number of patients with clinically significant changes in vital signs (blood pressure, pulse rate)

    Time frame: Baseline, day 1 and within 3-14 days after last glimepiride administration

  23. Number of patients with abnormal findings in 12-lead ECG (electrocardiogram)

    Time frame: Baseline, day 1 and within 3-14 days after last glimepiride administration

  24. Number of patients with abnormal findings in clinical laboratory tests

    Time frame: Baseline, day 1,4 and within 3-14 days after last glimepiride administration

  25. Number of patients with adverse events

    Time frame: Up to 34 days

  26. Assessment of tolerability by investigator on a 4-point scale

    Time frame: Within 3-14 days after last glimepiride administration

  27. Number of patients with abnormal findings in glucose bedside tests

    Time frame: Pre-dose and 1, 2, 4, 7, 10, 14, 24 hours after glimepiride administration on day 1

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2009 and a primary completion of Jun 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2014
First posted
Jun 24, 2014
Start
Apr 2009
Primary completionActual
Jun 2009
Last update
Jun 24, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02172261
Responsible party
Sponsor
First posted
Jun 24, 2014
Start date
Apr 2009
Primary completion
Jun 2009
Last update
Jun 24, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Empagliflozin

Start the discussion